iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Biocon considers selling its $1.5 billion generic API company

15 Dec 2023 , 02:37 PM

According to news report, Biocon is considering selling its generic active pharmaceutical ingredient (API) business, which is valued at approximately $1.5 billion, in order to lower its total debt. However, the company has not yet taken any significant steps in this regard.

‘Discussions with investment banks have taken place but the plan (for sale of generic API business) is still on the drawing board,’ according to the report.

Once Biocon’s cornerstone, the generic API business has seen a decline in its contributions to the company’s consolidated financials over time as the company has made strategic moves to realize its goal of becoming a key player in the global biosimilars market. The biosimilar business accounted for over half of Biocon’s Rs 11,550 crore top line in 2022–2023.

In November of last year, the Kiran Mazumdar-led company took a huge wager on biosimilars when it paid $3.34 billion to acquire a portfolio of medications from international pharmaceutical giant Viatris.

Debt from both Biocon Ltd. and its biosimilars division, Biocon Biologics, was used to finance that transaction. To finance the acquisition, Biocon Biologics obtained loans totaling $1.2 billion.

For feedback and suggestions, write to us at editorial@iifl.com

Biocon Biologics | LinkedIn

Related Tags

  • API Company
  • Biocon
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.